Oral Answers to Questions

Richard Burden Excerpts

Wednesday 10th April 2019 Commons Chamber

[The Prime Minister]

My hon. Friend has raised an important issue. Obviously, as he will appreciate, it is important that we ensure, first, that patients get access to cost-effective innovative medicines, but at a price that is fair and makes best use of NHS resources. That is the independent system that we have through the National Institute for Health and Care Excellence, which reviews the evidence. I understand that Biogen has submitted a revised submission to NICE in relation to Spinraza and that a meeting of NICE’s independent appraisal committee took place early in March to consider its recommendations. It is clear that everyone at the Department of Health and Social Care and in NICE recognises the significance of this drug, but we need to ensure that the decision taken is made on the basis of the clinical aspects, together with cost-effectiveness. That is what NICE will do in looking at the new offer.

[Richard Burden (Birmingham, Northfield) (Lab)]

When Melrose Industries took over GKN last year, it promised Ministers that it would back British manufacturing and not reduce the company’s defence capacity without the Government’s permission. Last week, GKN announced that it intended to close the Kings Norton plant, which makes windscreens for military and civilian aircraft. Will the Prime Minister tell GKN that the Government expect the company to abide by both the spirit and the letter of the undertakings given by Melrose last year?

[The Prime Minister]

I was not aware of the particular issue that the hon. Gentleman has raised. If I may, I will look into it and respond to him in writing.